SynBioBeta Speaker
Neeka Mashouf
Rubi Laboratories
CEO and Co-founder
Neeka Mashouf is co-founder and CEO of Rubi Laboratories, pioneering the next era of manufacturing by converting waste carbon into critical materials and chemicals using AI-optimized enzymes. Rubi's cell-free biocatalysis platform uses cascades of engineered enzymes to convert CO₂ into essential materials, enabling 10x lower capital costs than legacy systems, with 15 commercial partners across textiles, CPG, chemicals, and aerospace.Neeka's scientific journey began at 15, co-authoring research on artificial photosynthesis at the Lawrence Berkeley National Lab — launching a decade of work in energy materials, computational materials design, and polymer chemistry. She holds dual degrees in materials science and business from UC Berkeley and has been recognized on Forbes 30 Under 30, MIT 35 Under 35, and as a speaker at the World Economic Forum in Davos.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Neeka
This Year
•
-
Planetary Health
Biology Without Cells: The Rise of Cell-Free Biomanufacturing
Cell-free systems are redefining what’s possible in bioproduction. By bypassing the complexity of living cells, innovators can run enzyme cascades, prototype metabolic pathways, and produce high-value molecules with unmatched speed, precision, and purity. This new class of systems—from freeze-dried reactions to continuous cell-free reactors—enables rapid iteration, on-demand production, and scalable biochemistry without the need for fermentation tanks or long development cycles.
Get a Ticket
Featuring
Kavya Sharman
Phase Capital
Managing Partner
Amy Locks
Anzen Industries
CEO
Enzyme-stabilization expert building cell-free modular “enzyme reactors.”
Ravit Netzer
Scala Biodesign
CEO & Co-founder
Christopher Pirie
Decycle Bio
CEO
De-novo, cell-free enzyme cascades converting waste into chemicals
Neeka Mashouf
Rubi Laboratories
CEO and Co-founder
•
-
Planetary Health
Biology Without Cells: The Rise of Cell-Free Biomanufacturing
Cell-free systems are redefining what’s possible in bioproduction. By bypassing the complexity of living cells, innovators can run enzyme cascades, prototype metabolic pathways, and produce high-value molecules with unmatched speed, precision, and purity. This new class of systems—from freeze-dried reactions to continuous cell-free reactors—enables rapid iteration, on-demand production, and scalable biochemistry without the need for fermentation tanks or long development cycles.
Get a Ticket
Featuring
Kavya Sharman
Phase Capital
Managing Partner
Amy Locks
Anzen Industries
CEO
Enzyme-stabilization expert building cell-free modular “enzyme reactors.”
Ravit Netzer
Scala Biodesign
CEO & Co-founder
Christopher Pirie
Decycle Bio
CEO
De-novo, cell-free enzyme cascades converting waste into chemicals
Neeka Mashouf
Rubi Laboratories
CEO and Co-founder
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
